The market for transdermal drug delivery systems was valued at $52.4 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 4.9% from 2021 to $ 87.3 billion by 2030.
.jpg "The Global Transdermal Drug Delivery System Market 2020-2030 (USD Billion)")
The global transdermal drug delivery system (TDDS) market was valued at USD 5,737 million in 2020 and is projected to grow at a CAGR of 4.7% during the forecast period. Factors driving the growth of the transdermal drug delivery system market include growth in the prevalence of chronic diseases and high-tech advancements. Moreover, drug failure and recalls of transdermal drug delivery systems may hinder the market growth.
A major scientific advantage for persistent success is the ability of TDDS to provide sustained blood levels with minimal peak-to-trough variation via a non-oral, noninjectable route of delivery. A passive-delivery patch is also the only dosage form that can bridge the dosing interval gap between a once-a-day dosing, addressed by oral dosage forms, and a once-a-week or longer dosing, which is addressed by depot injection products. These unique features and other advantageous attributes of TDDS, when matched with the right drugs, provide compelling and differentiating medical benefits to all stakeholders.
The global transdermal drug delivery system market is categorized based on type and application. Based on type, the transdermal patches held the largest share in 2020, attributed to continuous drug delivery devices, reduced drug-drug interactions and increased bioavailability. By application, cardiovascular diseases to grow at a highest CAGR.
Regionally, North America accounted for the largest market share of the global transdermal drug delivery system market in 2020, while Asia Pacific is set to grow at a highest CAGR by 2028. Leading players of the global transdermal drug delivery system market include Hisamitsu Pharmaceutical, Novartis, Mylan, UCB, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Endo International and Purdue Pharma among others.
transdermal drug delivery system market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2030 |
| Study Period | 2018-2030 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2030 | $ 87.3 billion |
| Growth Rate | CAGR of 4.9 % during 2020-2030 |
| Segment Covered | Type, Application, Regions |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | Hisamitsu Pharmaceutical, Novartis, Mylan, UCB, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Endo International and Purdue Pharma among others. |
Key segments of the global transdermal drug delivery system market
Type Overview
- Transdermal Patches
- Transdermal Semisolids
Application Overview
- Pain Management
- Hormonal Applications
- Central Nervous System Disorders
- Cardiovascular Diseases
- Other Applications
Regional Overview
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Rest of the World
Reasons for the study
- Rise in incidence of chronic disorders
- Increase in adoption of third-generation transdermal drug delivery systems
What does the report include?
- The study on the global transdermal drug delivery system market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of type and application. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global transdermal drug delivery system market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global transdermal drug delivery system market
Consultants, analysts, researchers, and academicians looking for insights shaping the global transdermal drug delivery system market
Frequently Asked Questions (FAQ) :
The market value of transdermal drug delivery system market in 2030 was $ 87.3 billion.
North America dominated the market for transdermal drug delivery system market and accounted for the largest revenue share.
To get latest version of transdermal drug delivery system market report can be obtained on demand from the website.
One of the driving factors of this industry is the convenience and home use appeal for patients. Not only is first generation transdermal delivery safe and effective, it also has the benefit of being low cost. The use of physical enhancers may require electrical hand-held devices and so are more expensive, however they have the advantage of being able to deliver macromolecules and vaccines. As with most fast paced markets, advances in technology is a major driving force and the transdermal drug delivery market is no exception. The development of microneedles to enhance absorption has opened up market opportunities for transdermal peptide and vaccine delivery. An added advantage is the ability of microneedles to be incorporated in a single-use patch that is low cost and does not require an electrical current. A disadvantage of this method is that it is more invasive and so raises health and safety concerns. Moreover, it is anticipated that TDDS will revolutionize how vaccines are administered in the future. This technology would lend itself to infant vaccine programs, and also annual influenza vaccines which are particularly important in the geriatric and immunocompromised markets. Disadvantages of using the skin as a primary delivery receptacle include rash, sensitization and allergy. Currently, a number of active agents are regulatory approved for TDDS delivery, including sumatriptan (migraine), buprenorphine (chronic pain), oxybutynin (overactive bladder), rivastigmine (dementia), selegiline (depression), methylphenidate (ADHD), rotigotine (Parkinson’s Disease) and fentanyl (post-operative pain). Lidocaine is one of the original active ingredients used for transdermal delivery and is a major player within the local analgesic market.
The global transdermal drug delivery system market is segmented based on type and application. Based on type the market is split into transdermal patches and transdermal semisolids. Application wise the market is segmented into pain management, hormonal applications, central nervous system disorders, cardiovascular diseases and other applications.
The pain management segment is projected to account for the largest market share of the transdermal drug delivery systems market. Transdermal drug delivery poses a safer and preferred alternative to oral drug delivery as well as parenteral administration for nonsteroidal anti-inflammatory drugs due to various reasons. One advantage is that the transdermal route avoids the metabolism of the drug inside the liver and its rapid absorption inside the GI tract, thus avoiding the risk of internal bleeding and irritation. Additionally, TDDS typically avoids painful administration or other unwanted systemic side effects that may occur with oral administration. TDDS are designed to deliver a predetermined amount of drug through the stratum corneum and subsequently the systemic circulation. However, the choice of drug for TDDS depends on the size of the drug, as it should efficiently pass through the skin pores.
North America accounted for the largest share of the global transdermal drug delivery system market in 2020 and is expected to retain its position through 2028. Moreover, Asia is likely to show lucrative growth during the forecast period.
In India, transdermal drug delivery system has been in existence for a long time. Moreover, cardiovascular/ antihypertensive diseases are the major concern of death in India. Cardiovascular diseases account for more than 30% of deaths globally. The World Health Organization (WHO) estimates that low and middle income countries are disproportionately affected. About, 82% of CVD deaths take place in low and middle income countries and occur almost equally in men and women. In order to deliver therapeutic agents through the human skin for systemic effects of the cardiovascular/antihypertensive diseases, the comprehensive morphological, biophysical and physicochemical properties of the skin are to be considered. A lot of Indian pharmaceutical giants are seen pouring into R&D activities to develop TDDS for life threatening diseases. All in all, the Asian market for transdermal products has been in a significant upward trend that is probable to remain for the foreseeable future.